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Annexin A1 (ANXA1) is an endogenously produced anti-inflammatory protein, which
plays an important role in the pathophysiology of diseases associated with chronic
inflammation. We demonstrate that patients with type-2 diabetes have increased plasma
levels of ANXA1 when compared to normoglycemic subjects. Plasma ANXA1 positively
correlated with fatty liver index and elevated plasma cholesterol in patients with type-2
diabetes, suggesting a link between aberrant lipid handling, and ANXA1. Using a murine
model of high fat diet (HFD)-induced insulin resistance, we then investigated (a) the role
of endogenous ANXA1 in the pathophysiology of HFD-induced insulin resistance using
ANXA1−/− mice, and (b) the potential use of hrANXA1 as a new therapeutic approach
for experimental diabetes and its microvascular complications. We demonstrate that:
(1) ANXA1−/− mice fed a HFD have a more severe diabetic phenotype (e.g., more
severe dyslipidemia, insulin resistance, hepatosteatosis, and proteinuria) compared to
WT mice fed a HFD; (2) treatment of WT-mice fed a HFD with hrANXA1 attenuated the
development of insulin resistance, hepatosteatosis and proteinuria. We demonstrate here
for the first time that ANXA1−/− mice have constitutively activated RhoA. Interestingly,
diabetic mice, which have reduced tissue expression of ANXA1, also have activated
RhoA. Treatment of HFD-mice with hrANXA1 restored tissue levels of ANXA1 and
inhibited RhoA activity, which, in turn, resulted in restoration of the activities of Akt,
GSK-3β and endothelial nitric oxide synthase (eNOS) secondary to re-sensitization of
IRS-1 signaling. We further demonstrate in human hepatocytes that ANXA1 protects
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against excessive mitochondrial proton leak by activating FPR2 under hyperglycaemic
conditions. In summary, our data suggest that (a) ANXA1 is a key regulator of RhoA
activity, which restores IRS-1 signal transduction and (b) recombinant human ANXA1
may represent a novel candidate for the treatment of T2D and/or its complications.
Keywords: type-2 diabetes, metabolism, Annexin A1, nephropathy, hepatosteatosis, Rho A
INTRODUCTION
Obesity and metabolic syndrome are of global health concern
and are an independent risk factor of diseases characterized by
systemic inflammation such as type-2 diabetes mellitus (T2D),
non-alcoholic fatty liver disease (NAFLD/NASH) (1), chronic
kidney disease (CKD) (2), and cardiovascular disease (3). Even
with aggressive strategies to modulate both plasma lipid profiles
and blood glucose levels, microvascular complications develop
over time in patients with T2D (4). Indeed, ∼30% of patients
with T2D develop diabetic nephropathy, which is the leading
cause of end-stage renal disease (ESRD). Peripheral insulin
resistance drives a vicious pathophysiological cycle leading
to T2D, ectopic adiposity and chronic inflammation, coupled
with a down-regulation of pro-survival/anti-inflammatory
pathways. Identifying endogenous molecules that are both
anti-inflammatory and tissue protective agents will lead
to the discovery of novel drug target for the treatment
of diabetes.
Annexin A1 (ANXA1) is an endogenous anti-inflammatory
protein, principally known as a regulator of peripheral leukocyte
migration and a promoter of macrophage phagocytosis of
apoptotic neutrophils (5). ANXA1 is expressed by endothelial
cells, tubular epithelial cells, adipocytes, and low levels of ANXA1
can be detected in the circulation under physiological conditions.
We recently demonstrated that the plasma levels of ANXA1 are
elevated in patients with type-1 diabetes (6) andmultiple sclerosis
(7). Cristante et al. (7) demonstrated a mechanistic link between
RhoA andANXA1, whereby ANXA1 interacts with RhoA to alter
actin-polymerization and maintain blood brain barrier integrity.
RhoA has far reaching implications in many diseases including
type-2 diabetes, its activity is upregulated by oxidative stress
and hyperglycemia. Many strategies, which inhibit the Rac/RhoA
pathway, also reduce microvascular complications in diabetes via
a reduction in inflammation and fibrosis (8, 9).
In the present study, we use a translational approach to gain
a better insight into the role of ANXA1 in (a) patients with
T2D and (b) a murine model of high fat diet (HFD) induced
insulin resistance. Moreover, we investigated the effect of human
recombinant ANXA1 (hrANXA1) as a potential treatment for
experimental T2D and its microvascular complications.
METHODS
Human Studies and Subjects and
Ethic Statement
Human volunteers and patients were recruited within the general
population enrolled in the PLIC study (Progressione delle Lesioni
Intimali Carotidee) at the Center for the Study of Atherosclerosis,
SISA Bassini Hospital Cinisello B. Italy (Ethical approval
SEFAP/Pr0003F University of Milan 06/2/2001) (10). Patients
with T2D were identified from their clinical history, outpatient’s
registries and/oral hospital archives, following international
guidelines (11). Subjects included in the study were defined
as “normoglycemic” if the following criteria were met: No
self-reported T2D, patients are not being treated with glucose
lowering drugs and fasting glucose levels are below 110 mg/dL
(at least 3 previous controls). All patients and healthy volunteers
gave written informed consent in adherence to the Declaration
of Helsinki. Clinical data was collected, and biochemical analyses
were performed as previously described (12). Urinary albumin
levels were determined by immunoturbidimetry on fresh samples
of the morning. Fatty Liver Index was calculated from Body
Mass Index (BMI), waist circumference, gamma-glutamyl-
transpeptidase (GGT) and triglyceride levels in fasting condition
as previously described (13).
Healthy subjects” from the PLIC cohort were only included
if they had no evidence of hepatic steatosis (ultrasound
determined, not shown), renal damage or type-2 diabetes (T2D).
Clinical information [clinical and pharmacological history,
BMI, and waist-hip ratio (waist)] was collected during the
outpatient activity, which was part of the study design of
PLIC. Biochemical, lipid profile (LDL-C “LDL cholesterol
levels”), liver enzymes (including gamma-glutamyl-transferase),
C-reactive protein (CRP) and glucose level were determined as
previously described (12). Briefly, blood samples were drawn
after overnight fasting (10 h at least) from antecubital vein
and collected in EDTA tubes (BD Vacuette R©). Blood samples
were then centrifuged at 3,000 rpm for 12min in order to
separate plasma for glucose quantification. Determination was
performed by enzymatic method (hexokinase reaction) through
automatic sample analyzer (RX Daytona, Randox Laboratories
Ltd R©, Crumlin, UK).
Fatty liver Index (FLI) was determined as
previously described, according to the following
formula: FLI= (e0.953∗loge(triglycerides) +
0.139∗BMI + 0.718∗loge(GGT) + 0.053∗waistcircumference −
15.745)/(1 + e0.953∗loge(triglycerides) + 0.139∗BMI +
0.718∗loge(GGT)+ 0.053∗waistcircumference− 15.745)∗ 100.
Chronic kidney disease (CKD) and its stages (CKD3,
CKD4, and CKD5) were determined following determination
of glomerular filtration rate (GFR), according to validated
international criteria. When compared to healthy controls,
CKD patients had a GFR of <60 ml/min/1.73 m2 associated
with albuminuria (urinary albumin over 30 mg/g of total
urinary proteins).
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Use of Experimental
Animals-Ethics Statement
The experimental protocols used in this study have been
approved by the Animal Welfare Ethics Review Board (AWERB)
of Queen Mary University of London and the University of
Turin, the study was performed under license issued by the home
office (Procedure Project License; PPL: 70/8052) and committees
(DGSAF 0021573-P-12/11/2013 and DGSAF). Animal care was
in accordance with the Home Office guidance on Operation
of Animals (Scientific Procedures Act 1986) published by Her
Majesty’s Stationery Office and the Guide for the Care and Use
of Laboratory Animals of the National Research Council and are
in keeping with the European Directive (2010/63/EU) as well as
the Guide for the Care and Use of Laboratory Animals.
Animals and Experimental Procedures
This study was carried out on 10 weeks old ANXA1−/− mice on
a C57BL/6 background (14) and wild-type (WT) C57BL/6 mice,
housed in the same unit under conventional housing conditions
at 25 ± 2◦C. WT and ANXA1−/− mice were randomly assigned
either normal diet (chow) or high fat, high sugar diet (HFD)
(D12331diet, Research Diet Inc., USA). All mice had access to
food and water ad libitum. After 4 weeks of dietary manipulation,
mice were randomly assigned to a treatment group receiving
either with hrANXA1 (40 µg/kg, i.p.) or vehicle (Hepes 50mM,
NaCl 140mM i.p.) 5 days per week for 6 weeks. Mice were
harvested the morning after receiving the last dose of hrANXA1
(day 5 of week 6 of treatment). hrANXA1 was produced and
purified as previously published,∼0.5% of injected dose per gram
(ID/g) ANXA1 remained in the circulation 24 h post injection as
previously reported (15).
ELISA for ANXA1
A homemade sandwich ELISA was used to measure plasma
ANXA1 (16). Briefly, ELISA-treated plates (Nunc MaxiSorp,
ThermoScientific, UK) were incubated overnight with capture
antibody 20µg/ml (mouse monoclonal antibody, generated in
house) in bicarbonate buffer (25mM NaHCO3, 25mM Na2CO3,
pH 9.6). The plate was then washed 3 times with bicarbonate
buffer and blocked in blocking buffer (0.1% BSA, PBS) for 1 h
at 37◦C. Then 100 µl of sample and standard in assay diluent
(Tween-20 0.05% (v/v), PBS) were loaded and incubated for
1 h at 37◦C, then washed 5 times with wash buffer (0.9% (w/v)
NaCl, 0.05% (v/v) Tween-20, dH2O). Following this wells were
incubated with 1µg/ml of detecting antibody (rabbit polyclonal
anti-ANXA1; Invitrogen, UK) for 1 h at 37◦C. After 5 washes,
immuno-complexes were detected by adding the goat-anti-rabbit
IgG with conjugated alkaline phosphatase for 30min. After 5
washes, the substrate, p-nitrophenyl phosphate (Sigma Aldrich,
UK) was added and left for 30min for full development of color.
The plate was then read absorbance at 405 nm and corrected at
540 nm as a reference wavelength, using a spectrofluorometer
(Tecan Infinite M200 Pro, Tecan, Austria).
Oral Glucose Tolerance test (OGTT)
Mice were fasted for 6 h prior to testing, then given an oral bolus
of glucose (2 g/kg in H2O p.o.). Blood glucose was measured
from the tail vein at time 0 and then at 15min intervals for
120min using glucometer (Accu-Chek Compact System, Roche
Diagnostics); basal non-fasted blood glucose.
Blood and Biochemical Analysis
Serum triglyceride and total cholesterol were measured
by standard enzymatic assay using reagent kits (Hospitex
Diagnostics, Italy). Liver triglycerides were measured via a
colorimetric assay (Abnova Corporation, Germany). ALT and
urine and serum creatinine were measured by a commercial
veterinary testing laboratory (IDEXX, Wetherby, UK); serum
insulin and urine albumin were measured using commercially
available ELISA kits (Abcam, Cambridge, UK, and Bethyl
Laboratories, Montgomery, TX, USA).
Histological Analysis
Oil Red-O
Frozen liver samples were embedded in OCT, and cut in 10µm
sections. Section were brought to room temperature, fixed with
10% buffer formalin for 5min, washed with 60% isopropanol,
then saturated with Oil Red O (1% w/v, 60% isopropanol) for
15min, washed in 60% isopropanol and rinsed in distilled water.
The sections were then mounted in aqueous mounting medium
with coverslips. Images were acquired using a NanoZoomer
Digital Pathology Scanner (Hamamatsu Photonics K.K., Japan)
and analyzed using the NDP Viewer software. Additionally 10
randomly selected fields of view from each liver section were used
to assess lipid accumulation.
Periodic Acid Schiff’s
Kidney samples were obtained at the end of the experiment
and fixed in 10% neutral-buffered formalin for 48 h and
histology staining was performed. Briefly, kidney tissue was
embedding in paraffin and processed to obtain 4µm sections.
After deparaffinization and sections were rehydrated through
graded alcohol to distilled water. The sections were then
incubated with saturated in Periodic Acid Schiffs (Sigma, UK)
solution for 30min and washed in distilled water. Then sections
were then dehydrated through graded alcohols and cleared
before mounting with coverslips. Images were acquired using a
NanoZoomer Digital Pathology Scanner (Hamamatsu Photonics
K.K., Japan) and analyzed using the NDP Viewer software.
Additionally 10 randomly selected fields of view from each
kidney section were used to assess structural alteration of the
proximal convoluted tubules and general renal histopathology.
Western Blot Analysis
Semi-quantitative western blot analyses of phosphorylated
and/or total form of IRS-1, Akt, GSK-3β, endothelial nitric
oxide synthase (eNOS), ANXA1, RhoA, and MYPT1 were
carried out in tissue samples as described before (6). Briefly,
liver, skeletal muscle, and kidney samples were homogenized
in protein homogenization buffer and centrifuged at 1,300 g
for 5min at 4◦C. To obtain the cytosolic protein fraction,
supernatants were centrifuged at 16,000 g at 4◦C for 40min.
Protein content was determined on cytosolic extracts using
bicinchoninic acid (BCA) protein assay (Thermo Fisher
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Scientific, Rockford, IL). Proteins were separated by 8%
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to a polyvinyldenediflouoride
(PVDF) membrane, which were blocked with a solution of 5%
dry milk in TBS-Tween for 2 h. Membranes were incubated
with a primary antibody (1:1,000 rabbit anti-total IRS-1;
1:1,000 rabbit anti-pSer307 IRS-1; 1:1,000 rabbit anti-total Akt;
1:1,000 rabbit anti pSer473 Akt; 1:1,000 rabbit anti-total
GSK−3β 1:1,000 rabbit anti-pSer9GSK−3β; 1:200 rabbit
anti-ANXA1; 1:1,000 rabbit anti-total RhoA; 1:1,000 rabbit
anti-pSer188 RhoA; 1:1,000 rabbit anti-total MYPT1 and 1:1,000
rabbit anti-pSer853 MYPT1). Membranes were incubated with
a secondary antibody conjugated with horseradish peroxidase
(1:2,000) for 30min at room temperature and developed
with ECL detection system. The immunoreactive bands were
visualized by autoradiography and the densitometry analysis was
performed using Gel Pro Analyser 4.5, 2,000 software (Media
Cybernetics, Silver Spring, MD, USA). The membranes were
stripped and incubated with alpha tubulin monoclonal antibody
(1:5,000) and subsequently with an anti-mouse antibody
(1:2,000) to assess gel-loading homogeneity. Densitometry
analysis of the related bands is expressed as relative optical
density, and normalized using the related WT + vehicle or
sham band.
Oxygen Consumption Rate
HepG2 cells (3 × 105) were seeded in 96-well Seahorse plates in
serum free medium containing 5.5mM glucose, 25mM glucose,
25mM glucose + hrANXA1 (20µg/mL) or 25mM glucose +
hrANXA1 (20µg/mL) +WRW4 an FPR2 antagonist [0.9 mM-
Tocris- inhibits WKYMVm binding to FPR2 (IC50 = 0.23µM)]
and incubated for 48 h. to measure OCR, the medium was
replaced with XF Mitoassay medium (pH 7.4) and incubated
without CO2 for 30min. Then, basal OCR was measured
and wells were sequentially injected with: (1) oligomycin
(1.0µM), an ATP synthase blocker; (2) carbonyl cyanide
p-[trifluoromethoxy]-phenyl-hydrazone (FCCP) (0.5µM), a
proton ionophore; and (3) a mix of rotenone (0.5µM) and
antimycin A (0.5µM), inhibitors of electron transport. OCR was
measured three times following each injection with an interval
of 6min between each reading. Experiments were performed
three times in triplicate and all values of OCR were normalized
to protein content of individual wells. Data was gathered on
SeaHorse XFe96 Analyzer (Agilent Technologies) and data
analyzed using Wave Software (Agilent Technologies).
Image Stream
HepG2 cells were seeded into 6-well plates at a density of 1× 106
and then treated with DMEM containing glucose (5.5 or 25mM).
After 48 h, cells were harvested and fixed in paraformaldehyde
(2%) for 10min at room temperature and washed in PBS.
Cells were then blocked in blocking solution (PBS + 0.2%
BSA) for 30min at room temperature. To perform the staining
of FPR2 on the membrane, cells were then incubated with
primary anti-body [rabbit anti-FPR2 (1:50)] (Acris Antibodies)
(30min at room temperature), followed by incubation with
secondary anti-body [anti-rabbit AF488 (1:100)] (30min at room
temperature). From intracellular FPR2 and ANXA1 cells were
permeabilized with permeabilization solution (PBS + Tween20
0.5% v/v, 10min at room temperature); cells were then washed
and blocked in blocking solution (PBS + 0.2% BSA, 30min at
room temperature). Cells were then incubated with primary anti-
body [rabbit anti-FPR2 (1:50)] (Acris Antibodies) and mouse
anti-ANXA1 (Invitrogen (1:100) washed and incubated with
secondary anti-body (anti-rabbit AF647 (1:100) and anti-mouse
AF405 (1:100) (30min at room temperature), and then washed.
Imaging flow cytometry was performed on an ImageStreamx
Mark II operated by INSPIRE software (Amnis Corporation).
A sample of HEPG2 that were not incubated with antibodies
were collected at the same settings, in order to gate different cell
populations (negative or positive staining). In each experiment,
a template of settings was created and it was applied to all
files. A total of 10,000 events were collected for each sample,
and data were analyzed using IDEAS Application 6.1 software
(Amnis Corporation).
Human Phospho-Kinase Array
HepG2 cells were incubated in DMEM containing 5.5, 25, and
25mM glucose + hrANXA1 (20µg/mL) or 25mM glucose +
hrANXA1 (20µg/mL)+ WRW4 (0.9mM) and incubated for
48 h. Cells were washed in PBS containing protease inhibitors and
cell lysates extracted as per manufactures instructions. Protein
concentration was quantified and 600 µg of protein was used
per membrane of a Proteome Profiler, Human Phospho-kinase
Array (R&D Systems). After visualization of the spots, the signals
were measured using Image Studio LICOR, normalization was
carried as per manufacturers instruction and changes plotted in
a heat map expressed as fold change to 5.5mM glucose for each
individual phosphorylation site using PRISM.
Statistical Analysis
All data in the text and figures are presented as mean ±
standard error mean (SEM) of n observations, were n represents
the number patients per group (Figures 1,2), animals studied
(Figures 3–7) or technical replicates (Figure 8). All statistical
analysis was calculated using GraphPad Prism 7 for Mac
(GraphPad Software, San Diego, California, USA). Data without
repeated measurements was assessed by a one-way ANOVA
followed by Bonferroni correction. Some of the human data were
analyzed by Student’s t-test (data with normal distribution) or
Mann Whitney U-test (data that were not normally distributed).
Correlation studies were analyzed by linear regression using
Fishers F-test. In all cases a p < 0.05 was deemed significant.
RESULTS
Patients With Type-2 Diabetes Have
Elevated Plasma Levels of ANXA1
Correlated With Increased Dyslipidemia
and Fatty Liver Index
To gain a better understanding of the role of ANXA1 in man,
we compared the plasma levels of ANXA1 in gender- and
age-matched subjects with normoglycemia or T2D (Table 1).
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FIGURE 1 | Assessment of ANXA1 levels in patients with type-2 diabetes. (A) Plasma ANXA1 levels measured by ELISA in age and sex match normoglycemic
(n = 30) and patients with type-2 diabetes (n = 65). (B) Correlation in diabetic patients of plasma ANXA1 levels and: Fatty Liver Index (B), LDL-C (C), and total
cholesterol (D). Data is expressed as mean± SEM., ****p < 0.0001. (B–D) 95% confidence intervals are displayed of the microvascular and significance estimated
using Fishers F-test p < 0.05 was deemed significant.
FIGURE 2 | Correlation data of clinical markers in patients with type-2 diabetes and ANXA1. (A) Correlation of plasma CRP with BMI in diabetic patients.
(B) Correlation of plasma ANXA1 levels with BMI in diabetic patients. (C) Correlation of plasma ANXA1 levels with CRP in diabetic patients. (D) Correlation of CRP with
cholesterol in diabetic patients. (E) Correlation of CRP with LDL in diabetic patients. (F) Plasma ANXA1 levels in patients with diabetes ± CKD. (A–E) display 95%
confidence intervals are displayed of the linear regression and significance estimated using Fishers F-test p < 0.05 was deemed significant.
Of note, patients with T2D had significantly higher circulating
plasma levels of ANXA1 (Figure 1A) when compared with
normoglycemic subjects. Moreover, the plasma levels of ANXA1
in patients with T2D correlated positively with fatty liver index,
a surrogate marker of hepatic lipid accumulation (Figure 1B),
and serum LDL-C and total cholesterol (Figures 1C,D), thus
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FIGURE 3 | ANXA1 attenuates the development of obesity and insulin resistance in HFD fed mice. C57BL/6 or ANXA1−/− mice, fed a standard diet (chow) or a
high-fat diet (HFD) for 10 weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) five times per week between weeks 5 and 10. (A) ELISA
for ANXA1 levels were measured in serum isolated from whole blood at harvest, (n = 6) (B)Western blot analysis of kidney, liver, and skeletal muscle show a depletion
in ANXA1 which was restored by hrANXA1 treatment (n = 6/group). (C) Serum insulin levels were measured in plasma isolated from whole blood at harvest
(n = 6–10/group). (D) Basal non-fasted blood glucose was measured at week 10 1 h prior to harvest via the tail vain (n = 6–10/group). (E) Oral glucose tolerance was
assessed over 120min 1 week prior to harvest in WT mice. (F) Oral glucose tolerance was assessed over 120min 1 week prior to harvest in ANXA1−/− mice. (G) The
area under curve (AUC) of OGTT was calculated for respective groups and used for statistical analysis. Data analyses by a one-way ANOVA followed by a Bonferroni
post-hoc test and the mean is expressed mean ± SEM., *p < 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001; $p < 0.05 vs. WT + HFD; and $$p < 0.01, $$$p <
0.001 vs. ANXA1−/− + HFD.
implying a relation between elevated circulating ANXA1 levels
and a complex metabolic pattern, including altered glucose
control, hepatic steatosis and dyslipidemia. As expected, CRP
(a marker of chronic low-grade inflammation) correlated
positively with increased BMI in our cohort of patients with
T2D (Figure 2A). Interestingly circulating plasma ANXA1
did not correlate with either BMI or CRP (Figures 2B,C).
Additionally, we observed no correlation of CRP and lipid
levels (Figures 2D,E). Additionally, ANXA1 levels were not
further elevated in patients who presented with diabetes and
CKD (Figure 2F). This result is particularly interesting, as a
heightened level of systemic inflammation is classically seen
in patients with CKD. Taken collectively, these observations
suggest that the observed increase in plasma ANXA1 is
not a consequence of increased systemic inflammation,
but secondary to the altered metabolic state and aberrant
lipid handling.
ANXA1 Attenuates the Development of
Obesity and Insulin Resistance in HFD
Fed Mice
To gain a better understanding of the role of ANXA1
in the pathophysiology of T2D, we used a murine model
of HFD-induced insulin resistance, hepatic steatosis and
renal dysfunction (diabetic nephropathy). Consistent with
the observation in patients with T2D, mice fed a HFD
had elevated levels of circulating ANXA1 (Figure 3A). We
also show that the ANXA1 protein levels were dramatically
reduced in key target tissues (liver, kidney, and skeletal
muscle) of animals fed a HFD (Figure 3B) compared to chow
fed mice.
When compared to chow-fed mice, WT-mice fed a HFD
gained more weight (Table 2), had elevated levels of serum
insulin, higher (non-fasted) blood glucose levels and a significant
impairment in tolerance to oral glucose challenge (oral glucose
tolerance test, OGTT) (Figures 2C–G). ANXA1−/− fed a
HFD gained significantly more weight (Table 2), had higher
blood glucose levels (Figure 3D) and an even more severely
impaired OGTT (Figures 3F,G) when compared to HFD-
fed WT-mice. HFD-fed WT-mice treated with hrANXA1
had normal tissue levels of ANXA1 (Figure 3B), lower
serum insulin levels, lower (non-fasted) blood glucose levels
(Figures 3C,D) and an improved OGTT (Figures 3E,G)
when compared to HFD-fed WT-mice. Administration
hrANXA1 to ANXA1−/− mice (rescue experiment) resulted in
significantly lower serum insulin levels, blood glucose levels,
a reduction in weight gain and an improvement in OGTT;
suggesting that endogenous ANXA1 is a key mediator of
glucose homeostasis.
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FIGURE 4 | ANXA1 attenuates HFD induced development of peripheral insulin resistance. C57BL/6 or ANXA1−/− mice, fed a standard diet (chow), or a high-fat diet
(HFD) for 10 weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) five times per week between weeks 5 and 10. Western blot analysis
for Phosphorylation of Ser307 on IRS-1 in Skeletal muscle (A) or liver (D) and normalized to total IRS-1; for phosphorylation of Ser473 on Akt in the skeletal muscle
(B) and liver (E) and normalized to total Akt; for phosphorylation of Ser9 on GSK-3β in the skeletal muscle (C) and in the liver (F) and normalized to total GSK-3β. Data
were analyzed by a one-way ANOVA followed by a Bonferroni post-hoc test and the mean is expressed mean ± SEM., *p < 0.05, ***p < 0.001, ****p < 0.0001 vs.
WT + HFD; $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001 vs. ANXA1−/− +HFD.
ANXA1 Improves IRS-1 Signal Transduction
in HFD-Induced Insulin Resistance
As endogenous ANXA1 protected against the development
experimental diabetes and treatment with hrAXNXA1 improved
the diabetic phenotype of HFD-fedmice, we next investigated the
potential mechanisms underlying the observed beneficial effects
of both hrANXA1 and endogenous ANXA1.
When compared to WT-mice fed a chow diet, WT-mice fed
a HFD exhibited an increase in the degree of phosphorylation of
insulin substrate receptor-1 (IRS-1) on Ser307 in skeletal muscle
(Figure 4A) and liver (Figure 4D); as well as a decrease in the
phosphorylation of downstream effectors of the insulin signaling
pathway, protein kinase B (Akt) on Ser473 (Figures 3B,E) and
glycogen synthase kinase-3β (GSK-3β) on Ser9 in both skeletal
muscle and liver (Figures 4C,F). All of the above findings suggest
that WT-mice fed a HFD had developed peripheral insulin
resistance. ANXA1−/− mice fed a HFD exhibited a further
significant increase in the degree of phosphorylation of IRS-
1 on Ser307 in both skeletal muscle and liver (Figures 4A,D);
resulting in a decrease in the phosphorylation of Akt on
Ser473 (Figures 4B,E) and glycogen synthase kinase-3β (GSK-
3β) on Ser9 (Figures 4C,F). These data are consistent with the
more severe diabetic phenotype observed in ANXA1−/− mice
fed a HFD.
Treatment of WT-mice fed a HFD with hrANXA1
attenuated the increase in phosphorylation of IRS-1 on
Ser307, and the subsequent decrease in phosphorylation of
Akt on Ser473 and GSK-3β on Ser9 in both skeletal muscle
(Figures 4A–C) and liver (Figures 4D–F). Additionally,
when hrANXA1 was given to ANXA1−/− mice (rescue
experiment), all abnormal signaling events were restored
to that of WT mice fed a chow diet and highlighting
of ANXA1 as a signaling molecule in the IRS-1 signal
transduction pathway.
ANXA1 Attenuates Dyslipidemia, Steatosis,
Liver Injury, and Renal Dysfunction in HFD
Fed Mice
In addition to developing insulin resistance, WT-mice fed a
HFD had increased levels of serum triglycerides, cholesterol,
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FIGURE 5 | ANXA1 attenuates induced lipid accumulation, hepatic injury, and renal dysfunction. C57BL/6 or ANXA1−/− mice, fed a standard diet (chow) or a HFD
for 10 weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) five times per week between weeks 5 and 10. Measure of (A) Serum
triglyceride, (B) Serum cholesterol, (C) Liver triglyceride, (D) Serum aminotransferase (ALT), n = 6–8/group. (E) 18 h urine samples was collected and renal
dysfunction was measured by albumin to creatinine ratio (ACR), n = 6–8 per group. (F) Creatinine clearance was measured from urinary and serum creatinine,
n = 6–8 per group. (G): representative images of hepatic lipid deposition assessed by Oil Red-O staining. Panel (H): representative images of histological changes in
kidney structure assessed by periodic acid-Schiff staining, yellow arrows indicating brush borders of proximal tubules. Data were analyzed by a one-way ANOVA
followed by a Bonferroni post-hoc test and the mean is expressed mean ± SEM., *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. WT + HFD.
$p < 0.05, $$p < 0.01, $$$p < 0.001 vs. ANXA1−/− + HFD.
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FIGURE 6 | ANXA1 attenuates HFD induction of eNOS in the diabetic kidney C57BL/6 or ANXA1−/− mice, fed a standard diet (chow), or a high-fat high-sugar diet
(HFD) for 10 weeks, were treated with vehicle or hrANXA1 (40 µg/kg, i.p.) five times per weeks between weeks 5 and 10. At harvest kidney, liver and skeletal muscle
was harvested. Phosphorylation of eNOS was determined by western blot; a representative blot is shown and densitometry quantification of n = 3 independent
experiments. *p < 0.05 and $p < 0.05, $$$p < 0.001.
a 10-fold increase in liver triglyceride levels (Figures 5A–C)
associated with an increase in Oil Red-O staining in the liver
(Figure 5G), suggesting the development of dyslipidemia
and liver steatosis. Lipid deposition and steatosis in the
liver is associated with liver injury; WT-mice fed a HFD
had elevated serum ALT levels (Figure 5D) compared to
WT mice fed a chow diet. ANXA1−/− mice fed a HFD
had even significantly higher serum triglyceride levels,
further increased Oil Red-O staining in the liver and even
higher ALT levels when compared to WT mice fed a HFD
(Figures 5A–D,G). In contrast, WT-mice fed a HFD and treated
with hrANXA1 had significantly lower serum cholesterol and
liver triglyceride levels, less Oil Red-O staining in the liver and
significantly lower ALT levels (Figures 5A–D,G) compared
to HFD-fed WT-mice. Treatment of ANXA1−/− mice with
hrANXA1 (rescue experiment) resulted in a reduction in liver
triglyceride levels, serum ALT, and Oil Red-O accumulation
in the liver compared to ANXA1−/− mice fed a HFD
(Figures 5A–D,G). Taken together, these findings suggest that
ANXA1 protects against the development of dyslipidemia and
liver steatosis/injury.
T2D ultimately drives the development of microvascular
complications including diabetic nephropathy. WT-mice fed
a HFD exhibited an elevated albumin-to-creatinine ratio
(ACR) and decreased creatinine clearance (Figures 5E,F)
compared to chow-fed WT-mice, suggesting the development
of proteinuria (a marker of diabetic nephropathy) and
renal dysfunction. The development of proteinuria was
associated with significant morphological changes. WT-
mice fed a HFD have more vacuolar degeneration at the
level of the S1-S2 segment of the proximal convoluted
tubules, while other tubular structures of the nephron
remained histologically preserved (Figure 5H). There was
also a marked loss of brush boarders in the S1-S2 segment
of the proximal convoluted tubules (yellow arrows). All
histological markers of tubular degeneration were more
marked in the kidneys from ANXA1−/− mice fed on a
HFD (Figure 4H). Which correlated with ANXA1−/− mice
fed a HFD having further elevation in ACR (Figure 5E),
suggesting the development of more severe proteinuria. In
contrast, administration of hrANXA1 to HFD-fed WT-mice
attenuated the rise in ACR and the decrease creatinine clearance
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FIGURE 7 | ANXA1 attenuates RhoA induction in mice fed a HFD. C57BL/6 or ANXA1−/− mice, fed a standard diet (chow) or a high-fat high-sugar diet (HFD) for 10
weeks, were treated with vehicle or hrANXA1 (40 µg/kg, i.p.) five times per weeks between weeks 5 and 10. At harvest kidney, liver and skeletal muscle was
collected. (A–C) Phosphorylation of Ser188 on RhoA was normalized to total RhoA in kidney (A), liver (B), and skeletal muscle (C). (D–F) Phosphorylation of Thr853 on
MYPT1 was normalized to total MYPT1 in kidney (D), liver (E), and skeletal muscle (F). A representative blot is shown for each protein and densitometry quantification
of n = 3 experiments represented in the histograms. Data were analyzed by a one-way ANOVA followed by a Bonferroni post-hoc test and the mean is expressed
mean ± SEM., *p < 0.05, **p < 0.01, ***p <0.001, ****p < 0.0001 vs. WT + HFD; $p < 0.05, $$$p < 0.001, $$$$p < 0.0001 vs. ANXA1−/− +HFD.
(Figures 5E,F) and preserved the kidney from signs of tubular
degeneration (Figure 5H).
ANXA1 Regulates eNOS and RhoA
Activation in a Model of HFD-Induced
Insulin Resistance
One of the key drivers of proteinuria and, indeed, renal
dysfunction is renal hypertension, which is, in part driven by
the development of endothelial dysfunction.WT-mice fed a HFD
had a significant reduction in the phosphorylation of eNOS
on Ser1177 in the kidney (Figure 6) compared to chow-fed WT
animals; while hrANXA1 treatment significantly prevented the
reduction in phosphorylation of eNOS on Ser1177 (Figure 6).
Moreover, ANXA1−/− mice fed a HFD also demonstrated
significantly reduced phosphorylation of eNOS on Ser1177.
Interestingly, ANXA1−/− mice fed with HFD and treated
with hrANXA1 (rescue experiment) had no changes in the
phosphorylation of eNOS on Ser1177 (Figure 6), indicating that
hrANXA1 prevents the decline in eNOS phosphorylation seen in
ANXA1−/− mice fed with HFD.
Having shown that endogenous ANXA1 limits, and that
administration of hrANXA1 attenuates the development
of peripheral insulin resistance as well as liver injury and
kidney dysfunction caused by a HFD, we further explored the
potential mechanism(s) underlying the observed beneficial
effects of ANXA1. Activation of RhoA plays a key role
in the development of both peripheral insulin resistance
and in the development of microvascular complications of
diabetes (9). We have previously demonstrated that ANXA1
interacts with RhoA (7). Here we demonstrate that the
tissue levels of ANXA1 are decreased in mice fed a HFD
(Figure 2B). This resulted in reduced phosphorylation of
RhoA on Ser188 (increased GTPase activity) and in an increase
in the phosphorylation of downstream effector MYPT1 on
Thr853 in the kidney (Figures 7A,D), liver (Figures 6B,E),
and skeletal muscle (Figures 7C,F), when compared to
chow-fed WT-mice.
Interestingly, ANXA1−/− mice also have a reduced
phosphorylation of RhoA on Ser188 (Figures 7A–C), and an
increased phosphorylation of MYPT1 on Thr853 (Figures 7D–F)
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FIGURE 8 | ANXA1 protects human hepatocytes from excess proton leak via FPR2. HepG2 cells were grown for 48 h in 5.5mM glucose, 25mM glucose, 25mM
glucose + hrANXA1, or 25mM glucose + hrANXA1 + WRW4. (A) Oxygen consumption rate was assessed using SeaHorse analyzer. (B) Basal OCR, and
(C) ATP-linked OCR, and (D) proton leak. (E) Expression and localization of FPR2 and ANXA1 assessed by immunofluorescent staining and visualized using image
stream. (F) 1 × 106 HepG2 cells were grown in 6 well-plates and protein isolated to assess phosphorylation state of 43 proteins using human phospho-proteome
profiler. (B–D) Data were analyzed by a one-way ANOVA followed by a Bonferroni post-hoc test and the mean is expressed mean ± SEM., **p < 0.01, ****p < 0.0001
vs. HepG2 + 25mM glucose. (F) Data expressed as fold change to HepG2 + 5.5mM glucose of pooled samples from 3 independent experiments.
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(regardless of dietary manipulation) in kidney and skeletal
muscle, suggesting that ANXA1−/− mice have constitutively
activated RhoA-GTPase. Treatment of ANXA1−/− mice
fed a HFD with hrANXA1 (rescue experiment) resulted
in an increase in the degree of phosphorylation of RhoA
on Ser188 (Figures 7A–C) and attenuation of the degree of
phosphorylation on MYTP1 on Thr853 (Figures 7D–F), in liver,
kidney, and skeletal muscle; demonstrating conclusively that
ANXA1 regulates RhoA activity.
TABLE 1 | Detail of patients included in the study.
Normoglycemic T2D
Number (n) 30 65
Age (years) 71 ± 0.4 69 ± 0.9
Gender (F%) 13 (43) 46 (35)
Fasting glucose (mg/dL) 101.3 ± 1.2 171.7 ± 5.6*
Hb1Ac (%) N/A 7.37 ± 0.1
BMI (kg/m2) 26.3 ± 0.6 31.4 ± 0.8*
Waist Circumference 91.3 ± 1.5 105.91 ± 1.74*
Total cholesterol (mg/dL) 189.5 ± 4.8 187.27 ± 5.48
HDL-C (mg/dL) 59.7 ± 1.7 48.02 ± 1.85*
LDL-C (mg/dL, Friedewald) 109.7 ± 4.3 109.61 ± 4.70
Triglycerides (mg/dL) 100.1 ± 5.3 148.26 ± 17.4*
C-Reactive Protein (mg/dL) 0.12 ± 0.02 0.58 ± 0.2*
Alanine Aminotransfersae (ALT) (U/L) 19.54 ± 0.96 31.89 ± 4.8*
Aspartate Aminotransferase (AST) (U/L) 24.08 ± 0.61 26.71 ± 3.1*
Gamma Glutamyl Transpeptidase (GGT) (U/L) 28.6 ± 3.15 35.16 ± 2.7*
Fatty Liver Index (%) 37.1 ± 5.7 66.14 ± 3.31*
Creatinine (mg/dL) 0.9 ± 0.04 1.8 ± 0.1*
GFR (mL/min) 71.3 ± 2.34 29.7 ± 1.8*
Urinary albumin (mg/g urinary protein) N/A 202.0 ± 48.1
Number of patients per group, age, gender, fasting glucose, Hb1Ac, BMI, waist
circumference serum, cholesterol, HDL, LDL-C, triglyceride, C-reactive protein (CRP),
ALT, AST, GGT, FLI, creatinine, GFR, and urinary albumin. Experimental groups:
Normoglycemic (n = 30) and patients with type-2 diabetes T2D, (n = 65). Data analyzed
by unpaired Student’s t-test (normally distributed data) or Mann Whitney U-test (data
that are not normally distributed) and expressed as mean ± SEM. *p < 0.05; NA, data
not available.
From a therapeutic point of view, treatment of WT HFD-
fed mice with hrANXA1, also restored the tissue levels of
ANXA1 in liver, kidney, and skeletal muscle (Figure 2B).
This prevented the reduction of the phosphorylation of
RhoA on Ser188 (Figures 7A–C), and the associated increase
in phosphorylation of MYPT1 on Thr853 (Figures 7D–F)
observed in HFD-fed WT-mice. These findings support the view
that ANXA1 regulates the activity of RhoA in experimental
diabetes, which, in turn, limits the development of peripheral
insulin resistance and protects the kidney and liver from
functional decline.
ANXA1 Protects Against Excessive Proton
Leak via FPR2 in Human Hepatocytes
One of the major sites of both lipid and glucose handling
is the liver. Therefore, we wanted to investigate whether
ANXA1 is involved in the regulation of energy homeostasis
in human hepatocytes. Therefore, in order to evaluate whether
hepatic mitochondrial respiration was altered under high
glucose conditions, oxygen consumption rate (OCR) was
measured (Figure 8A). HEPG2 cells grown in high glucose
medium had higher basal OCR (Figure 8B), increased ATP-
linked OCR (Figure 8C) leading to excessive proton leak
(Figure 8D), which can lead to the formation of reactive
oxygen species and cellular damage. When HEPG2 cells were
incubated in high glucose (25mM) medium in the presence of
hrANXA1, hrANXA1 attenuated the increases in basal OCR
(Figure 8B), ATP-linked OCR (Figure 8C), and proton leakage
(Figure 7D). We hypothesized that the observed beneficial
effects of treatment with hrANXA1 are mediated though the
FPR2 receptor. Interestingly, expression levels of FPR2 was not
altered by exposure of HEPG2 cells to high glucose (25mM)
medium, whereas ANXA1 levels were decreased (Figure 8E).
Using a specific FPR2 antagonist, we were able to block the
effects of hrANXA1 on basal OCR (Figure 8B), ATP-linked
OCR (Figure 8C), and proton leak (Figure 8D) suggesting the
beneficial effects of hrANXA1 in reducing excessive proton leak
are, indeed, FPR2 mediated.
TABLE 2 | Animals biochemistry.
Wild Type ANXA1 -/-
Chow Chow + hrANXA1 HFD+ Vehicle HFD + hrANXA1 Chow HFD + Vehicle HFD + hrANXA1
Body weight (g) 9.790 ± 0.602* 9.857 ± 0.674* 16.81 ± 0.479 12.87 ± 0.455* 4.550 ± 0.276$ 13.89 ± 0.772 7.00 ± 0.447$
Epididymal fat (mg) 1.963 ± 0.163* 2.100 ± 0.255* 3.570 ± 0.291 2.867 ± 0.253* 2.288 ± 0.067$ 5.609 ± 0.246 4.361 ± 0.007$
Inguinal fat (mg) 1.250 ± 0.128* 1.275 ± 0.149* 2.320 ± 0.243 1.833 ± 0.212* 0.714 ± 0.051$ 1.842 ± 0.096 1.370 ± 0.094$
Blood glucose (mmol/L 8.438 ± 0.541* 7.682 ± 0.29* 13.86 ± 0.6621 9.088 ± 0.442* 8.650 ± 0.493$ 19.56 ± 1.224 8.483 ± 0.541$
Serum Insulin (ng/mL) 6.6941.282* 7.110 ± 1.061* 18.73 ± 2.454 7.860 ± 0.697* 5.321 ± 0.238$ 20.54 ± 1.271 13.47 ± 0.817$
OGTT (AUC) 84.42 ± 4.506* 84.96 ± 3.659* 110.7 ± 3.659 89.42 ± 0.999* 87.65 ± 4.716$ 127.6 ± 3.767 99.93 ± 3.560$
Body weight gain from baseline, epididymal fat weight, inguinal fat weight, blood glucose, serum insulin, and OGTT AUC were measured in WT C57BL/6 or ANXA1−/− mice fed a
standard diet (chow) or a high-fat diet (HFD) for 10 weeks. HFD-mice were treated with either vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) five times per weeks between
weeks 4 and 10. Data are expressed as mean± SEM of 7–10 mice per group. Data were analyzed by a one-way ANOVA followed by a Bonferroni post-hoc test, *p < 0.05 vs. WT +
HFD or $p < 0.05 vs. ANXA1 + HFD.
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Effects of hrANXA1 on MAPK and Akt
Pathway Are FPR2 Mediated in
Human Hepatocytes
To get a better understanding of the signaling pathways
modulated by hrANXA1 in HepG2 cells during exposure
to high glucose, the phosphorylation states of 43 potentially
relevant pathways were measured using a human phospho-
kinase proteome profiler array (Figure 8F and Figure S1). Our
results demonstrate that HepG2 cells grown in high glucose
medium (25mm) had an increase in phosphorylation of key
members of theMAPK pathway (p38, JNK, ERk1/2, and RSK1/2)
and in the Akt pathway (Akt, GSK-3B, p70, and PRAS40),
while key members of the pro-inflammatory JAK/STAT pathway
exhibited decreased inhibitory phosphorylation (Stat2 and
Stat5a). When HepG2 cells were grown in high glucose medium
and treated with hrANXA1, the observed increases seen in
the phosphorylation of the MAPK (p38, JNK, ERk1/2, and
RSK1/2) and the Akt pathway (GSK-3B, p70, and PRAS40) were
attenuated. Additionally, AMPKa2 phosphorylation was further
increased in the presence of hrANXA1. Pre-incubation with an
FPR2 antagonist abolished all of the above effects of treatment
with hrANXA1, strongly suggested that ANXA1 is signaling
through FRP2 (Figure 8F).
DISCUSSION
The key findings of our study are that patients with T2D
have elevated plasma ANXA1 levels, which correlate positively
with fatty liver index and serum lipid levels, but not with
markers of systemic inflammation, suggesting that the ANXA1
levels in patients with T2D are not regulated by systemic
inflammation, but are a consequence of aberrant lipid handling.
To elucidate the role of ANXA1 in the pathophysiology of
obesity/metabolic syndrome, we used a model of HFD-induced
insulin resistance in WT and ANXA1−/− mice. Consistent
with our patient data, mice fed a HFD showed elevated serum
ANXA1 levels, while their tissue levels were reduced (see below).
ANXA1−/− mice fed a HFD developed a more severe diabetic
phenotype (compared to WT mice) as indicated by higher
fasting glucose levels, increased impairment in the oral glucose
tolerance test and increased impairment of insulin signaling
(IRS-1, Akt, and GSK-3β). Additionally, treatment of WT-mice
fed a HFD with hrANXA1 reduced the diabetic phenotype,
restored IRS-1 and Akt (liver and skeletal muscle) and eNOS
(kidney) activity. ANXA1−/− mice fed on a HFD also developed
severe dyslipidemia, hepatosteatosis (lipid accumulation in the
liver) and renal dysfunction (proteinuria), while the therapeutic
administration of hrANXA1 attenuated both hepatosteatosis
and the renal dysfunction/proteinuria caused by HFD. HFD-
fed mice had lower intracellular levels of ANXA1 in the
kidney, liver and skeletal muscle resulting in the activation of
small GTPase RhoA and of the downstream effector MYTP1:
This key finding was confirmed in ANXA1−/− mice, which
had constitutively activative RhoA. Treatment with hrANXA1
restored intracellular ANXA1 levels, reduced RhoA activation
and restored IRS-1 signaling. Thus, we demonstrate here for
the first time a mechanistic link between ANXA1 levels, RhoA
activity and IRS-1 signaling. Treatment of human hepatocytes
with hrANXA1 also reduced the mitochondrial proton leak in an
FPR2-dependent manner. All of the above findings support the
conclusions that endogenous ANXA1 prevents the development
of insulin-resistance and associatedmicrovascular complications,
while pharmacologically administered hrANXA1 attenuates
the development of metabolic and secondary microvascular
complications in experimental T2D.
What, then, is the mechanism(s) by which ANXA1 attenuates
insulin resistance in experimental T2D and protects against
the development of secondary complications? The observed
impairment in glucose tolerance seen in mice fed on a HFD is,
in part, mediated by alterations in insulin signaling in liver and
skeletal muscle. The IRS-1/Akt/GSK-3β signaling cascade is a
key regulator of glucose transportation, glycogen synthesis, and
energy metabolism (glycolysis) (17). Peripheral insulin resistance
is attributed to an increase in the phosphorylation of Ser307 on
IRS-1; this uncouples IRS-1 from the insulin receptor blunting
the ability of insulin to signal through its receptor, which, in
turn, reduces GLUT4 translocation to the cell surface to facilitate
glucose uptake in peripheral organs, leading to hyperglycemia
(18). Mice fed a HFD showed increased phosphorylation of
Ser307 on IRS-1 (in the liver/skeletal muscle), which was further
augmented in ANXA1−/− mice. In contrast, treatment with
hrANXA1 attenuates this increase in the phosphorylation of
Ser307 on IRS-1 resulting restoration/maintenance of normal
glucose levels in the blood (19).
Many of the beneficial effects of anti-diabetic drugs are
mediated through inhibition of the GTPase RhoA. Metformin
reduces RhoA activity and activates AMPK (20, 21), while
Fasudil, a selective RhoA inhibitor used to treat diabetic
nephropathy, improves insulin signaling and nephropathy by
correcting glucose and lipid homeostasis in obese Zucker
rats (22–24). Statins, which are best known for their lipid-
lowering effects, also ameliorate the progression of diabetic
nephropathy, and both effects have been attributed to inhibition
of RhoA/ROCK (25–29). Interestingly, RhoA activation is
inhibited by ANXA1 (7), suggesting an original mechanistic link
between ANXA1 levels, RhoA activation and the development
of insulin resistance. We demonstrate that mice fed a HFD
have an increase in the circulating levels of ANXA1, but this
was associated with reduced expression in skeletal muscle, liver,
kidney, which (in turn) resulted in activation of RhoA. However,
we do not know whether the circulating ANXA1 measured in
animals and man is inactive or whether the subsequent treatment
restores the loss of the biological activity; though we need to
take in consideration the limited comparability of the mouse
model vs. the human condition. Moreover, we also demonstrate
that ANXA1−/− mice have constitutively activated RhoA activity
suggesting that ANXA1 is a regulator of RhoA activity. Thus, we
propose that endogenous ANXA1 is a regulator of RhoA/ROCK
activity under physiological conditions. Indeed, treatment of
HFD-fed mice with hrANXA1 restored intracellular ANXA1
levels/signaling (Figure 2B), modulated RhoA phosphorylation
and re-stabilized the insulin receptor (resulting in reduced
phosphorylation of IRS-1) allowing restoration of insulin
signaling and glucose homeostasis. Cristante et al. (7) have
previously demonstrated in the brainmicrovascular endothelium
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that ANXA1 and RhoA co-precipitate together suggesting a
direct molecular interaction. Here we demonstrate for first
time a mechanistic link between ANXA1, RhoA, and IRS-1
signaling in vivo.
Impairments in insulin sensitivity are associated with
excessive lipid deposition (18). WTmice fed on a HFD developed
dyslipidemia, had excessive fat accumulation in their peripheral
fat beds (Table 1) and in the liver causing hepatic steatosis and
liver injury (elevated ALT levels), all of which were more severe
in ANXA1−/−mice. In contrast, mice fed aHFD and treated with
hrANXA1 show reduced adiposity, and a reduction in lipid and
triglyceride accumulation in the liver. Collectively, our findings
suggest that ANXA1 reduces the development of hepatic steatosis
and the associated liver injury by inhibition of RhoA activity
and restoration of IRS-1 signaling. Indeed, our human data shed
further light on the role of ANXA1 in lipid homeostasis, as
ANXA1 plasma levels correlate positively with increased lipids
in both the liver and the circulation, but do not correlate with
systemic inflammation, suggesting a new biological function of
ANXA1 beyond those of as an anti-inflammatory mediator.
We also report here that mice fed a HFD have reduced
phosphorylation (Ser473) and, hence, reduced activation of Akt.
Activated Akt regulates inflammatory and pro-survival responses
(30). We also show in human hepatocytes that treatment
with ANXA1 re-activated Akt in an FPR2-dependent manner.
One consequence of inhibition of Akt is that organs are less
resistant to stressor stimuli including hyperglycemia and/or
hyperlipidemia and subsequently develop organ injury (15). In
contrast, restoration of the degree of activation of the Akt
pathway reduces organ injury in many conditions associated
with inflammation including sepsis-induced organ dysfunction
(31, 32), hemorrhagic shock-induced organ dysfunction (33, 34),
and diabetes (6, 18). The N-terminal peptide of ANXA1 (Ac2-
16) also reduces tissue injury by activating Akt in experimental
models of cardiac/renal reperfusion injury (35, 36) and non-
alcoholic steatohepatitis (37). Activation of Akt also results in
inhibition GSK-3β (Ser9 phosphorylation) resulting in activation
of glycogen synthase, which converts glucose to glycogen for
storage in the liver. Here we demonstrate that mice fed on
a HFD have decreased activation of GSK-3β, which could
result in a reduction in glycogen synthesis and increased blood
glucose levels. In contrast, mice treated with hrANXA1 have
restored phosphorylation of GSK-3β; allowing for the enzymatic
conversion of glucose to glycogen.
We demonstrate using extracellular flux assay that
hyperglycemia alter mitochondrial function resulting in the
production of excessive protons, that can lead to the production
of excessive ROS, which primarily damage the mitochondria.
Here we shown that hrANXA1 protects the mitochondria from
the detrimental effects of hyperglycemia in an FPR2-dependent
manner. Consistent with previous in vivo data (6) we show
that the treatment of human hepatocytes grown in under high
glucose with hrANXA1attenuates the activation of MAPK and
restores Akt and GSK-3β activity. Incubation of HEPG2 cells
with normal (5.5mM) results in co-localization of ANXA1
and FPR2 on the plasma membrane. In contrast, treatment
of these cells with high glucose (25mM) results in a clear
separation of the localization of ANXA1 and FPR2 (Figure 8).
Such data clearly suggests that high glucose conditions effects
ANXA1 distribution and its inability to work in an autocrine
way (38).
Insulin resistance results in the development of microvascular
complications including diabetic nephropathy. ANXA1−/− mice
fed a HFD have more severe renal dysfunction (proteinuria and a
reduction in GFR) when compared to WT mice fed on a HFD
diet. Patients with T2D display endothelial dysfunction, which
is associated with an increased cardiovascular risk (39). Several
lines of evidence suggest that decreased eNOS phosphorylation
is a molecular mechanism linking aberrant metabolism and
vascular dysfunction: (i) eNOS phosphorylation is diminished
in diabetes, hypercholesterolemia, and atherosclerosis (40–
42), (ii) anti-diabetic drugs including statins and PPAR
agonists increase eNOS phosphorylation (37), and (iii) signaling
molecules including insulin, IGF-1, and leptin increase eNOS
phosphorylation (39). Here we demonstrate that mice fed on
a HFD have decreased eNOS phosphorylation (in the kidney),
which was restored by hrANXA1 treatment. The present study
shows that mice fed a HFD have decreased Akt and eNOS
activity, while both of these signaling events are attenuated by
treatment with hrANXA1. Indeed, inhibition of RhoA/ROCK by
statins or other selective inhibitors leads to the up regulation
and activation of eNOS (43), potentially through restoration
of Akt signaling (39). We also demonstrate that inhibition
of RhoA attenuates the activity of MYTP1. MYPT1 is a key
regulator of vascular tone within vascular smooth muscle.
Activated (phosphorylated) MYPT1 actively phosphorylates
myosin delaying its ability to relax, therefore, inducing prolonged
contraction (44, 45) suggesting there could be a link between
ANXA1 and the development of hypertension (however this
warrants further investigation).
We report here for the first time that plasma levels of AXNA1
are also elevated in patients with T2D, thus supporting the
hypothesis that increased circulating ANXA1 levels are indicative
of an immune-metabolic state. Obesity is one of the strongest
etiological predictors for developing T2D and of adverse
cardiovascular outcomes. Here we clearly demonstrate a positive
correlation between increased hepatic steatosis (fatty liver index),
waist circumference (Table 1) and elevated plasma ANXA1 levels
(Figure 1A); suggesting that high ANXA1 levels may also be a
biomarker of the development of fatty liver disease (although
this hypothesis warrants further investigation). Dyslipidemia is
a key predictive factor for both the development of T2D and
adverse cardiovascular events. Here we show for the first time a
strong positive correlation between elevated total cholesterol and
LDL-C and elevated plasma ANXA1 levels. Critically, ANXA1
levels were not correlated with CRP and marker of chronic
inflammation. This is consistent with our previous finding
showing that ANXA1 levels did not correlate with CRP in
patients with type-1 diabetes. We hypothesize that ANXA1 is
released from cellular stores into the circulation in response
to an aberrant physiological conditions (6) where it is known
to signal in both an autocrine and paracrine manner through
Formyl-Peptide receptors to elicit both anti-inflammatory and
tissue protective effects (5). Two independent lines of evidence
support this (1) ANXA1 levels are elevated in both patients and
mice with T2D and (2) tissue levels of ANXA1 are decreased in
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HFD-fed mice (Figure 1) suggesting it has been released from
intracellular stores.
CONCLUSIONS
In conclusion, we report here for the first time that mice fed
a HFD develop insulin resistance, while endogenous ANXA1
dampens the development of both the diabetic phenotype and the
associated hepatic steatosis and nephropathy (proteinuria). Most
notably, treatment with hrANXA1 re-establishes normal insulin
signaling and attenuates the development of hepatosteatosis
and diabetic nephropathy. ANXA1 regulates and inhibits RhoA
activity in vivo. In murine diabetic tissues, expression of
ANXA1 is decreased allowing for the activation of RhoA,
while treatment with hrANXA1 inhibits RhoA activity, decreases
insulin resistance, and restores Akt and eNOS signaling. Finally,
we demonstrate that patients with T2D have elevated plasma
levels of ANXA1. Thus, we propose that elevated levels of
ANXA1may represent a novel biomarker for the development of
hepatosteatosis and that hrANXA1 or its peptide mimetics may
be useful in the treatment of T2D and/or its complications.
AUTHOR CONTRIBUTIONS
GP, MC, AB, GN, CT, and ES drafted the manuscript
and provided important intellectual content. RAL performed
Seahorse and image stream analysis. FC, DC, AC, RM, MA, and
JC acquired data on signaling. MB and MS acquired Elisa data.
LG, ALC, and CR provided human sample collection and clinical
data set and discussion. CR expressed and purified the human
recombinant ANXA1, MY contributed to the discussion. GP,
CT, and ES are the guarantors of this work. All authors made
substantial contributions to conception and design, acquisition
of data and interpretation of data, reviewed, and approved
the manuscript.
FUNDING
We would like to thank the following funding bodies for
their support: the British Heart Foundation (Award number:
FS/13/58/30648) to GP and (Award number: 16/60/32739) to
MS; University of Turin (Ricerca Locale Linea B 2015 and Linea
A 2016) to MC; the William Harvey Research Foundation to
CT; Bart’s and The London Charity Centre of Diabetic Kidney
Disease (programme grant: 577/2348) to CT and MY; and
FISM Fondazione Italiana Sclerosi Multipla (Cod. 2014/R/21)
to ES. The work of the authors is supported by: Fondazione
Cariplo [2015-0524] and [2015-0564] (ALC) and [2016-0852]
(GN); H2020 REPROGRAM [PHC-03-2015/667837-2] (ALC);
Telethon Foundation [GGP13002] (GN); Ministero della Salute
[GR-2011-02346974] (GN); Aspire Cardiovascular Grant [2016-
WI218287] (GN).
ACKNOWLEDGMENTS
Parts of the study were presentated as a poster presentation
at Experimental Biology 17, Chicago, U.S.A, where the work
won a research recognition award from the American Society of
Physiology—Renal Section.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.00571/full#supplementary-material
Supplementary Figure 1 | 1 × 106 HepG2 cells were grown for 48 h in 5.5mM
glucose, 25mM glucose, 25mM glucose + hrANXA1, or 25mM glucose +
hrANXA1 + WRW4. Protein was isolated to assess phosphorylation state of 43
proteins using human phospho-proteome profiler, 23 are reported in the figure.
Data expressed as fold change to HepG2 + 5.5mM glucose of pooled samples
from 3 independent experiments.
REFERENCES
1. Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, et al. Prevalence of nonalcoholic
fatty liver disease in patients with type 2 diabetes mellitus. Medicine. (2017)
96:e8179. doi: 10.1097/MD.0000000000008179
2. Rhee CM, Ahmadi SF, Kalantar-Zadeh K. The dual roles of obesity in
chronic kidney disease. Curr Opin Nephrol Hypertens. (2016) 25:208–16.
doi: 10.1097/MNH.0000000000000212
3. Mandviwala T, Khalid U, Deswal A. Obesity and cardiovascular disease:
a risk factor or a risk marker? Curr Atheroscler Rep. (2016) 18:21.
doi: 10.1007/s11883-016-0575-4
4. Brownlee M. Biochemistry and molecular cell biology of diabetic
complications. Nature. (2001) 414:813–20. doi: 10.1038/414813a
5. Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors
of the resolution of inflammation. Nat Rev Immunol. (2009) 9:62–70.
doi: 10.1038/nri2470
6. Purvis GSD, Chiazza F, Chen J, Azevedo-Loiola R, Martin L, Kusters
DHM, et al. Annexin A1 attenuates microvascular complications through
restoration of Akt signalling in a murine model of type 1 diabetes.
Diabetologia. (2017) 61:482–95. doi: 10.1007/s00125-017-4469-y
7. Cristante E, McArthur S, Mauro C, Maggioli E, Romero IA,
Wylezinska-Arridge M, et al. Identification of an essential endogenous
regulator of blood-brain barrier integrity, and its pathological and
therapeutic implications. Proc Natl Acad Sci USA. (2013) 110:832–41.
doi: 10.1073/pnas.1209362110
8. Biro M, Munoz MA, Weninger W. Targeting Rho-GTPases in immune
cell migration and inflammation. Br J Pharmacol. (2014) 171:5491–506.
doi: 10.1111/bph.12658
9. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, et al. RhoA/Rho-
kinase contribute to the pathogenesis of diabetic renal disease. Diabetes.
(2008) 57:1683–92. doi: 10.2337/db07-1149
10. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano
AL,et al. Catapano thickness effects of fractalkine receptor variants on
common carotid artery intima-media effects of fractalkine receptor variants
on common carotid artery intima-media thickness. Stroke. (2006) 37:1558–61.
doi: 10.1161/01.STR.0000221803.16897.22
11. Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N. Comment
on: american diabetes association. standards of medical care in
diabetes−2011. Diabetes Care. (2011) 34(Suppl 1):S11–61. doi: 10.2337/
dc11-0174
12. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, et al.
High density lipoprotein cholesterol levels are an independent predictor of
the progression of chronic kidney disease. J Intern Med. (2013) 274:252–62.
doi: 10.1111/joim.12081
13. Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G,
et al. PCSK9 deficiency results in increased ectopic fat accumulation in
Frontiers in Immunology | www.frontiersin.org 15 March 2019 | Volume 10 | Article 571
Purvis et al. Annexin A1 Protects Against Microvascular Complications
experimental models and in humans. Eur J Prev Cardiol. (2017) 24:1870–7.
doi: 10.1177/2047487317724342
14. Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ, et al.
Aberrant inflammation and resistance to glucocorticoids in annexin 1−/−
mouse. FASEB J. (2003) 17:253–5. doi: 10.1096/fj.02-0239fje
15. Kusters DHM, Chatrou ML, Willems BAG, De Saint-Hubert M, Bauwens M,
van der Vorst E, et al. Pharmacological treatment with annexin A1 reduces
atherosclerotic plaque burden in LDLR-/- mice on western type diet. PLoS
ONE. (2015) 10:e0130484. doi: 10.1371/journal.pone.0130484
16. Goulding N, Godolphin JL, Sharland PR, Maddison PJ, Sampson M,
Peers SH, et al. Anti-inflammatory lipocortin 1 production by peripheral
blood leucocytes in response to hydrocortisone. Lancet. (1990) 335:1416–8.
doi: 10.1016/0140-6736(90)91445-G
17. White MF. The IRS-1 signaling system. Curr Opin Genet Dev. (1994) 4:47–54.
doi: 10.1016/0959-437X(94)90090-6
18. Chiazza F, Couturier-Maillard A, Benetti E, Mastrocola R, Nigro D,
Cutrin JC, et al. Targeting the NLRP3 inflammasome to reduce diet-
induced metabolic abnormalities in Mice. Mol Med. (2015) 21:21011025.
doi: 10.2119/molmed.2015.00104
19. Gual P, Le Marchand-Brustel Y, Tanti J-F. Positive and negative regulation
of insulin signaling through IRS-1 phosphorylation. Biochimie. (2005) 87:99–
109. doi: 10.1016/j.biochi.2004.10.019
20. Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, Rio M, Sagan C,
Savineau JP, et al. Protective role of the antidiabetic drug metformin against
chronic experimental pulmonary hypertension. Br J Pharmacol. (2009)
158:1285–94. doi: 10.1111/j.1476-5381.2009.00445.x
21. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue
L, et al. Metformin activates AMP-activated protein kinase in primary
human hepatocytes by decreasing cellular energy status. Diabetologia. (2011)
54:3101–10. doi: 10.1007/s00125-011-2311-5
22. Kanda T, Wakino S, Homma K, Yoshioka K, Tatematsu S, Hasegawa K, et al.
Rho-kinase as a molecular target for insulin resistance and hypertension.
FASEB J. (2005) 20:169–71. doi: 10.1096/fj.05-4197fje
23. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N,
et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and
nephropathy in insulin-resistant diabetic rats. J Endocrinol. (2007) 192:595–
603. doi: 10.1677/JOE-06-0045
24. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, et al. Rho kinase
inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Diabetes. (2009) 58:215–26. doi: 10.2337/db08-0762
25. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl
coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. (2001)
21:1712–9. doi: 10.1161/hq1101.098486
26. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects
of statins: lipid reduction and beyond. J Clin Endocrinol Metab. (2002)
87:1451–8. doi: 10.1210/jcem.87.4.8412
27. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G.
Mechanisms of statin-mediated inhibition of small G-protein function. J Biol
Chem. (2005) 280:34202–9. doi: 10.1074/jbc.M505268200
28. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal
outcomes: a meta-analysis. J Am Soc Nephrol. (2006) 17:2006–16.
doi: 10.1681/ASN.2006010012
29. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of
RhoA/ROCK signaling ameliorates progression of diabetic nephropathy
independent of glucose control. Diabetes. (2008) 57:714–23. doi: 10.2337/
db07-1241
30. Cantley LC. The Phosphoinositide 3-kinase pathway. Science. (2002)
296:1655–7. doi: 10.1126/science.296.5573.1655
31. Chen J, Kieswich JE, Chiazza F, Moyes AJ, Gobbetti T, Purvis GSD,
et al. IκB kinase inhibitor attenuates sepsis-induced cardiac dysfunction
in CKD. J Am Soc Nephrol. (2017) 28:94–105. doi: 10.1681/ASN.20150
60670
32. Khan AI, Coldewey SM, Patel NSA, RogazzoM, CollinoM, YaqoobMM, et al.
Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice
via activation of the β-common receptor. Dis Model Mech. (2013) 6:1021–30.
doi: 10.1242/dmm.011908
33. Yamada N, Martin LB, Zechendorf E, Purvis GSD, Chiazza F, Varrone
B, et al. Novel synthetic, host-defense peptide protects against organ
injury/dysfunction in a rat model of severe hemorrhagic shock. Ann Surg.
(2017) 268:1. doi: 10.1097/SLA.0000000000002186
34. Sordi R, Nandra KK, Chiazza F, Johnson FL, Cabrera CP, Torrance HD,
et al. Artesunate protects against the organ injury and dysfunction induced
by severe hemorrhage and resuscitation. Ann Surg. (2017) 265:408–17.
doi: 10.1097/SLA.0000000000001664
35. Qin C, Buxton KD, Pepe S, Cao AH, Venardos K, Love JE, et al. Reperfusion-
induced myocardial dysfunction is prevented by endogenous annexin-A1
and its N-terminal-derived peptide Ac-ANX-A1 2−26. Br J Pharmacol. (2013)
168:238–52. doi: 10.1111/j.1476-5381.2012.02176.x
36. Facio FN, Sena AA, Araújo LP, Mendes GE, Castro I, Luz MAM, et al.
Annexin 1 mimetic peptide protects against renal ischemia/reperfusion
injury in rats. J Mol Med. (2011) 89:51–63. doi: 10.1007/s00109-010-
0684-4
37. Locatelli I, Sutti S, Jindal A, VacchianoM, Bozzola C, Reutelingsperger C, et al.
Endogenous annexin A1 is a novel protective determinant in nonalcoholic
steatohepatitis in mice. Hepatology. (2014) 60:531–44. doi: 10.1002/he
p.27141
38. McArthur S, Yazid S, Christian H, Sirha R, Flower R, Buckingham J, et al.
Annexin A1 regulates hormone exocytosis through a mechanism involving
actin reorganization. FASEB J. (2009) 23:4000–10. doi: 10.1096/fj.09-131391
39. Huang PL. eNOS, metabolic syndrome and cardiovascular disease.
Trends Endocrinol Metab. (2009) 20:295–302. doi: 10.1016/j.tem.2009.
03.005
40. Li Q, Atochin D, Kashiwagi S, Earle J, Wang A, Mandeville E, et al.
Deficient eNOS Phosphorylation is a mechanism for diabetic vascular
dysfunction contributing to increased stroke size. Stroke. (2013) 44:3183–8.
doi: 10.1161/STROKEAHA.113.002073
41. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low
density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from
plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. (1999)
274:32512–9. doi: 10.1074/jbc.274.45.32512
42. Ponnuswamy P, Schröttle A, Ostermeier E, Grüner S, Huang PL, Ertl
G, et al. eNOS Protects from atherosclerosis despite relevant superoxide
production by the enzyme in apoE−/− Mice. PLoS ONE. (2012) 7:e30193.
doi: 10.1371/journal.pone.0030193
43. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide.
Circ Res. (2005) 97:1232–5. doi: 10.1161/01.RES.00001965
64.18314.23
44. Lee JH, Palaia T, Ragolia L. Impaired insulin-stimulated myosin phosphatase
Rho-interacting protein signaling in diabetic Goto-Kakizaki vascular
smooth muscle cells. Am J Physiol Cell Physiol. (2012) 302:C1371–81.
doi: 10.1152/ajpcell.00254.2011
45. Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S.
Heart failure and kidney dysfunction: epidemiology, mechanisms and
management. Nat Rev Nephrol. (2016) 12:610–23. doi: 10.1038/nrneph.20
16.113
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Purvis, Collino, Loiola, Baragetti, Chiazza, Brovelli, Sheikh,
Collotta, Cento, Mastrocola, Aragno, Cutrin, Reutelingsperger, Grigore, Catapano,
Yaqoob, Norata, Solito and Thiemermann. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 16 March 2019 | Volume 10 | Article 571
